Browse by topic
Subscribe to our blog

Overcoming barriers in physician partnerships

Pharmaceutical companies have aspired to make medication adherence programs more effective for years. A report from Credit Suisse shows that increased adherence could substantially increase revenue from 2020–2026 for leading pharma companies such as ...
Read

How pharma is advancing medication adherence

We live in exciting times for adherence, and the pharma industry is playing a critical role, according to Mark Degatano, a pharmaceutical industry analytics expert who is on the advisory board of AllazoHealth. Degatano’s expertise comes from 24 ...
Read

Why pharma companies should utilize real-world data

Eli Lilly and Co. and Abbott have made headlines recently for using real-world evidence to prove better adherence and outcomes for its diabetes products. More pharma companies are likely to utilize real-world data to support brands as access ...
Read

How new patient data rules benefit payers

Starting next year payers may have new opportunities to collect real world data that was previously fragmented, incomplete and in some cases unavailable.
Read

Dispelling the myths of artificial intelligence in healthcare

As common as artificial intelligence has become in our daily lives — from Google’s Alexa, to Facebook’s data-driven ads, to Waze’s application of driver data to find the best route — it is little understood. The public tends to believe that AI ...
Read

Latest trends in healthcare AI: Pharmacies, payers, and pharma

  Here’s a survey of how pharmacies, payers, and pharmaceutical companies are using artificial intelligence right now.
Read

Optimizing DIR contracts and achieving adherence measures

 
Read

The coming revolution of AI analytics and healthcare

As our Medicaid health plan clients tell us, it’s a numbers game. When it comes to reimbursement, states evaluate the performance of plans using the National Care Quality Alliance’s HEDIS and other endorsed measurements. But making measurable ...
Read

Healthcare AI: Why defining constraints upfront is critical

AllazoHealth COO William Grambley explains in this article: “You need to be explicit about AI program constraints upfront. Otherwise you can get to unintended consequences.”
Read